Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa.
作者信息
Friedman Blake E, English Joseph C
机构信息
Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania.
出版信息
JAAD Case Rep. 2018 Jun 6;4(6):543-545. doi: 10.1016/j.jdcr.2018.03.007. eCollection 2018 Jul.
Abstract
摘要
相似文献
1
Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa.
JAAD Case Rep. 2018 Jun 6;4(6):543-545. doi: 10.1016/j.jdcr.2018.03.007. eCollection 2018 Jul.
2
An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
J Am Acad Dermatol. 2014 Feb;70(2):243-51. doi: 10.1016/j.jaad.2013.09.044. Epub 2013 Dec 4.
3
Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis.
JAMA Dermatol. 2018 May 1;154(5):592-595. doi: 10.1001/jamadermatol.2018.0141.
4
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Arthritis Rheum. 2004 Jan;50(1):277-90. doi: 10.1002/art.11487.
5
Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
J Clin Aesthet Dermatol. 2017 Sep;10(9):36-38. Epub 2017 Sep 1.
6
Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
J Dermatolog Treat. 2018 Aug;29(5):441-449. doi: 10.1080/09546634.2017.1395806. Epub 2017 Nov 10.
7
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.
J Am Acad Dermatol. 2011 Oct;65(4):790-798. doi: 10.1016/j.jaad.2010.07.010.
8
IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact.
Cytokine. 2001 Jun 7;14(5):272-82. doi: 10.1006/cyto.2001.0884.
9
Regulation of interleukin-1 receptor antagonist by Th1 and Th2 cytokines.
Am J Physiol. 1995 Jul;269(1 Pt 1):L92-8. doi: 10.1152/ajplung.1995.269.1.L92.
引用本文的文献
1
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.
JID Innov. 2023 Aug 10;3(5):100220. doi: 10.1016/j.xjidi.2023.100220. eCollection 2023 Sep.
2
Sarcoidosis: Pitfalls and Challenging Mimickers.
Front Med (Lausanne). 2021 Jan 11;7:594275. doi: 10.3389/fmed.2020.594275. eCollection 2020.
3
Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.
Front Med (Lausanne). 2020 Nov 24;7:594133. doi: 10.3389/fmed.2020.594133. eCollection 2020.
4
Granulomatous Cutaneous Drug Eruptions: A Systematic Review.
Am J Clin Dermatol. 2021 Jan;22(1):39-53. doi: 10.1007/s40257-020-00566-4.
5
Effect of High Selective Serotonin-Reuptake Inhibitor Doses on the Development and Treatment of Sarcoid-Like Reaction.
Case Rep Med. 2020 Apr 25;2020:9751837. doi: 10.1155/2020/9751837. eCollection 2020.
6
Topiramate-induced reactive granulomatous dermatitis.
JAAD Case Rep. 2019 Jun 3;5(6):501-503. doi: 10.1016/j.jdcr.2019.03.017. eCollection 2019 Jun.
7
Systematic review of immunomodulatory therapies for hidradenitis suppurativa.
Biologics. 2019 May 13;13:53-78. doi: 10.2147/BTT.S199862. eCollection 2019.
8
IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α.
J Clin Lab Anal. 2019 Jul;33(6):e22903. doi: 10.1002/jcla.22903. Epub 2019 May 17.
本文引用的文献
1
Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma.
JAAD Case Rep. 2017 Apr 14;3(3):208-211. doi: 10.1016/j.jdcr.2017.02.015. eCollection 2017 May.
2
Isolated subcutaneous sarcoid-like granulomatous inflammation occurring at injection sites: 3 patients treated successfully with minocycline.
JAAD Case Rep. 2017 Feb 4;3(1):74-77. doi: 10.1016/j.jdcr.2016.12.004. eCollection 2017 Jan.
3
Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept.
Rev Assoc Med Bras (1992). 2016 Nov;62(8):718-720. doi: 10.1590/1806-9282.62.08.718.
4
Pembrolizumab-associated sarcoidosis.
JAAD Case Rep. 2016 Jul 27;2(4):290-3. doi: 10.1016/j.jdcr.2016.06.004. eCollection 2016 Jul.
5
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.
RMD Open. 2016 Jul 15;2(2):e000239. doi: 10.1136/rmdopen-2015-000239. eCollection 2016.
6
Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses.
Cell Mol Immunol. 2017 Jan;14(1):22-35. doi: 10.1038/cmi.2016.25. Epub 2016 Jun 6.
7
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Chest. 2016 May;149(5):e133-6. doi: 10.1016/j.chest.2015.10.082.
8
Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.
BMC Pulm Med. 2016 Feb 11;16:30. doi: 10.1186/s12890-016-0193-5.
9
Cutaneous sarcoidosis at insulin injection sites.
CMAJ. 2016 Jun 14;188(9):674. doi: 10.1503/cmaj.150572. Epub 2016 Jan 18.
10
Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Dermatology. 2015;231(4):378-84. doi: 10.1159/000439400. Epub 2015 Oct 10.
Zotero 插件